Sharemaestro Newsreel

PTCT Maintained by Barclays -- Price Target Raised to $122

Barclays has maintained an "Overweight" rating for PTC Therapeutics (PTCT) and increased its price target to $122.00 from $120.00. Despite this positive analyst outlook, GuruFocus indicates the stock is significantly overvalued at $71.52 against a GF Value of $37.55, with a mixed GF Score …

Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings

SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 9.99% in Cellectar Biosciences Inc. Class A Common Stock, totaling 851,285 shares. This disclosure, made via a SCHEDULE 13G SEC filing, indicates shared voting and dispositive power over these shares. The …

Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A

Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has reported a beneficial ownership of 9.96% in CytomX Therapeutics (CTMX). This group collectively holds shared voting and dispositive power over 21,703,093 shares of common stock. The disclosure was made …

Innovative Eyewear Q2 EPS $(0.26) beats estimate, sales rise 74%

Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake

Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has disclosed a beneficial ownership of 6.78% in Celldex Therapeutics, Inc. This ownership translates to shared voting and dispositive power over 5,322,908 shares of Celldex's common stock. The filing, a …

Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares

Highbridge Capital Management, LLC has disclosed a beneficial ownership of 6.1% in Annovis Bio, Inc., which is tied to 2,775,578 shares of common stock issuable upon the exercise of warrants. This stake is calculated based on 42,541,868 outstanding common shares after a referenced offering …

Llamada de resultados del T2 de 2026 de Dyadic International (DYAI): progreso comercial y riesgo de liquidez

Dyadic International (DYAI) reportó ingresos estables en el segundo trimestre de 2026 de $961,000, con una pérdida neta que aumentó a $2.1 millones, y sus ingresos del primer semestre crecieron un 52% a $2.1 millones. A pesar de los progresos comerciales, la empresa finalizó …

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?

Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's earnings, which historically correlates strongly with stock price movement, making CDXS an attractive investment. The …

Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics

Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have reported a 4.01% beneficial ownership stake in Vera Therapeutics, Inc. Class A common stock. This represents 2,890,059 shares with shared voting and dispositive power. The filing indicates that their ownership is …

Eton Pharmaceuticals Stock Jumps 38% as Guidance Reset Tests Valuation

Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has raised its price target for Upstream Bio (NASDAQ:UPB) to $9.00 from $8.00, maintaining a "neutral" rating. This new target suggests a potential upside of 29.22% from the stock's current price of $6.96. The company recently reported a quarterly loss …

Sensus Healthcare, Inc. Q2 2026: Revenue $2.29M, EPS $(0.53) — 10-Q Summary

Sensus Healthcare, Inc. (SRTS) reported a significant decline in its Q2 2026 financial results, with revenue falling to $2.29M and diluted EPS at $(0.53). This downturn was primarily attributed to fewer system sales, a shift towards Fair Deal Agreements and rental arrangements impacting revenue …

Butterfly Network (NYSE:BFLY) Shares Down 4.4% - Here's What Happened

Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.7% - Here's Why

HTFL Maintained by Wells Fargo -- Price Target Raised to $39

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

CABA Maintained by Wells Fargo -- Price Target Lowered to $3.00

Wells Fargo has maintained an Equal-Weight rating for Cabaletta Bio Inc (CABA) but lowered its price target from $4.00 to $3.00, reflecting a cautious outlook. The company's GF Score™ of 34/100 indicates significant weaknesses in profitability and growth, despite strengths in financial stability and …

AVAH Q2 Earnings Call Highlights Higher Growth Targets

What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?

Pulmonx Corporation (LUNG) has been identified as a strong momentum stock by Zacks Equity Research, boasting a Momentum Style Score of B and a Zacks Rank of #2 (Buy). The company has shown significant short-term and long-term price performance, outperforming both its industry and …

Reflecting On Healthcare Technology Stocks’ Q2 Earnings: GoodRx (NASDAQ:GDRX)

Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A

Aquamarine Financial (Cayman) Ltd has reported a beneficial ownership of 2,512,175 shares in Oramed Pharmaceuticals Inc., which constitutes 6.04% of the common stock as of June 30, 2026. The filing, an amended Schedule 13G/A, indicates that Aquamarine holds sole voting and sole dispositive power …

Scienture Holdings Q2 non-GAAP EPS of -$0.07, revenue of $0.34M

* Scienture Holdings, Inc. press release [https://seekingalpha.com/pr/20619685-scienture-reports-q2-2026-results-with-approximately-510-percent-sequential-revenue-growth] (SCNX [https://seekingalpha.com/symbol/SCNX]): Q2 Non-GAAP EPS of -$0.07. * Revenue of $0.34M. * Net loss for Q2 2026 narrowed 58% YoY to $2.82M from $6.72M in Q2 2025. * Gross profit was $0.34M with a gross margin of …

Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management

Eventide Asset Management, LLC, through its Eventide Healthcare & Life Sciences Fund, has reported a beneficial ownership of 3,891,019 shares of Immix Biopharma (IMMX) common stock, representing a 5.6% stake. This Schedule 13G filing indicates that Eventide holds sole voting and dispositive power over …

What is driving nursing shortages? It's 'not a supply problem'

Meghan Fitzgerald, Columbia Professor, Grey Ghost Capital Private Equity Investor and on the board of Tenet Healthcare joins Yahoo Finance's Julie Hyman to explain why the U.S. healthcare crisis stems from nurse retention and burnout rather than a labor supply shortage. Video Transcript 00:00 …

[6-K] Valneva SE Current Report (Foreign Issuer)

Valneva SE (VALN) filed a Form 6-K Current Report with the SEC on August 14, 2026, which incorporated a press release dated the same day. This report indicates the company's ongoing compliance with foreign private issuer reporting requirements and includes information relevant to its …

Brad Bickham Returns as Addus HomeCare Interim COO

Addus HomeCare Corporation announced that Heather Dixon, president and chief operating officer, has left the company. Brad Bickham, former president and chief operating officer, will return as interim COO for one year, effective immediately. CEO Dirk Allison expressed gratitude for Dixon's contributions and confidence …

Is Alpha Tau Medical’s (DRTS) Steepening Loss Curve Reframing Its High-Risk Innovation Strategy?

Alpha Tau Medical (DRTS) reported a significant widening of its net loss to US$68.75 million in the first half of 2026, up from US$18.81 million a year prior, leading to increased concerns about its funding risk. Despite the company's focus on clinical progress for …

Fate Therapeutics Initiates Potentially Registrational Trial of Off-the-Shelf CAR T-Cell Therapy FT819 for Lupus Nephritis

Fate Therapeutics has started RECLAIM-LN, a Phase 2 registrational trial for its off-the-shelf CAR T-cell therapy FT819, targeting refractory lupus nephritis. This follows positive Phase 1 safety and efficacy data. The trial, developed with FDA interaction, aims to enroll 53 patients, with preliminary data …

Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake

An investor, Laurence W. Lytton, and the Lytton-Kambara Foundation have each reported a 4.99% beneficial ownership stake in Aytu BioPharma (AYTU), according to a recent Schedule 13G/A filing. Each party beneficially owns 545,946 shares, consisting of common stock and warrants, with all voting and …

Wells Fargo & Company Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00

Wells Fargo & Company has lowered its price target for Cabaletta Bio (NASDAQ:CABA) from $4.00 to $3.00, while maintaining an "equal weight" rating, suggesting a potential upside of 12.57%. Analyst opinions are varied, with MarketBeat reporting a "Moderate Buy" consensus and a $15.33 average …

MeiraGTx (NASDAQ:MGTX) Given New $27.00 Price Target at Royal Bank Of Canada

West Pharmaceutical (WST) Upgraded to Buy: Here's Why

West Pharmaceutical (WST) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's underlying business and could lead to a favorable impact on its stock price. The …

Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?

Edwards Lifesciences Corporation EW is entering the second half of 2026 with faster structural heart growth and better operating leverage. Second-quarter revenues rose 13.6% to $1.74 billion, while adjusted earnings increased 16.4% to 78 cents per share. The question is whether that momentum warrants …

Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These

Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1%

Short interest in Indaptus Therapeutics (NASDAQ:INDP) dramatically decreased by 64.1% in July, totaling 93,141 shares as of July 31st. Despite beating consensus EPS estimates for the quarter, the stock trades near its one-year low, and analyst sentiment remains negative with an average "Sell" rating. …